Lisata Therapeutics (FRA:8NE) ROCE % : -58.12% (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Lisata Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lisata Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was -58.12%.

Lisata Therapeutics ROCE % Historical Data

The historical data trend for Lisata Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lisata Therapeutics ROCE % Chart

Lisata Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-67.84

-68.76

-47.36

-75.12

-44.05

Lisata Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-42.64	-45.92	-43.33	-47.16	-58.12

Lisata Therapeutics ROCE % Calculation

Lisata Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-23.574	/	( ( (68.944 - 6.026)	+	(50.154 - 6.043) )	/ 2 )
	=	-23.574	/	( (62.918	+	44.111)	/ 2 )
	=	-23.574	/	53.5145
	=	-44.05 %

Lisata Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-24.292	/	( ( (50.154 - 6.043)	+	(44.381 - 4.906) )	/ 2 )
	=	-24.292	/	( ( 44.111	+	39.475 )	/ 2 )
	=	-24.292	/	41.793
	=	-58.12 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Lisata Therapeutics (FRA:8NE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lisata Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Lisata Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lisata Therapeutics (FRA:8NE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lisata Therapeutics Inc (FRA:8NE) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

LSTA:USA

Address

110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920

Website

https://www.lisata.com

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.

Lisata Therapeutics (FRA:8NE) Headlines

No Headlines